Gaining Exclusive License for Ruxolitinib Cream for the Treatment of Vitiligo and Atopic Dermatitis
2023-05-17

Gaining Exclusive License for Ruxolitinib Cream for the Treatment of Vitiligo and Atopic Dermatitis

Selected for the “Top 25 Listed Pharmaceutical Companies” of “Top 100 Hong Kong Listed Companies” for the Third Consecutive Year
2023-02-24

Selected for the “Top 25 Listed Pharmaceutical Companies” of “Top 100 Hong Kong Listed Companies” for the Third Consecutive Year

Won the Awards of “Listed Biopharma with the Most Growing Value” and “Overseas Listed Company with the Most Growing Value”.
2022-12-30

Won the Awards of “Listed Biopharma with the Most Growing Value” and “Overseas Listed Company with the Most Growing Value”.

Won “Best Information Disclosure Award” in China IR Annual Awards
2022-12-23

Won “Best Information Disclosure Award” in China IR Annual Awards

Awarded “Best Hong Kong Stock Connect listing Company”
2022-12-20

Awarded “Best Hong Kong Stock Connect listing Company”

Selected as the “Annual Growth Value Awards” of 2022 Annual Golden Award
2022-12-16

Selected as the “Annual Growth Value Awards” of 2022 Annual Golden Award

Selected into “TOP20 ESG Competitiveness of Chinese Pharmaceutical Listed Companies”
2022-10-21

Selected into “TOP20 ESG Competitiveness of Chinese Pharmaceutical Listed Companies”

Gaining Exclusive License for BMI Botulinum Toxin Product
2022-10-08

Gaining Exclusive License for BMI Botulinum Toxin Product

Shenzhen Kangzhe was once again listed in “Shenzhen Top 500 Enterprises”

Shenzhen Kangzhe was once again listed in “Shenzhen Top 500 Enterprises”

Acquired 60% equity interest in Heling and obtained exclusive product rights of the dermatology-grade skincare products “Heling Soothing Series”
2022-08-19

Acquired 60% equity interest in Heling and obtained exclusive product rights of the dermatology-grade skincare products “Heling Soothing Series”

Initiated the Southeast Asia business; obtained exclusive product rights of Insulin Series Products in 11 Southeast Asian countries
2022-09-02

Initiated the Southeast Asia business; obtained exclusive product rights of Insulin Series Products in 11 Southeast Asian countries

Obtained exclusive product rights of EyeOP1 Glaucoma Treatment Device in Mainland China, 11 Southeast Asian countries and other regions, and acquired approximately 33.4% equity interest in Eye Tech Care
2022-08-12

Obtained exclusive product rights of EyeOP1 Glaucoma Treatment Device in Mainland China, 11 Southeast Asian countries and other regions, and acquired approximately 33.4% equity interest in Eye Tech Care